Small interfering RNA for regulating TRPV1 gene activity and application thereof

By designing specific small interfering RNA sequences and combining them with modified nucleotides and ligands, the TRPV1 channel protein is directly inhibited, solving the problem that existing dry eye treatments cannot cure pain and inflammation, and achieving a highly effective treatment with low side effects.

CN122256340APending Publication Date: 2026-06-23YOUJIA (HANGZHOU) BIOMEDICAL TECH CO LTD
0 Cites 0 Cited by

Patent Information

Application Number
CN202511956996.8
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2024-12-23
Filing Date
2025-12-23
Publication Date
2026-06-23

AI Technical Summary

Technical Problem

Existing treatments for dry eye cannot effectively target the TRPV1 channel protein, making it difficult to cure pain and inflammation. Furthermore, existing medications have significant side effects and low compliance, making them unsuitable for patients with moderate to severe dry eye.

Method used

We designed specific small interfering RNA (siRNA) sequences to form double strands by complementing the TRPV1 gene, and then directly inhibited TRPV1 gene expression by binding modified nucleotides and ligands. The siRNA was then delivered to the target tissue through a specific delivery system to form conjugates and improve efficiency.

Benefits of technology

It effectively inhibits TRPV1 gene expression, reduces pain and inflammatory response, has a long-lasting effect, low side effects, high patient compliance, reduces the frequency of medication, and avoids discomfort.

✦ Generated by Eureka AI based on patent content.
Patent Text Reader

Abstract

The invention belongs to the field of biological medicine, and particularly relates to small interfering RNA for regulating and controlling TRPV1 gene activity, the small interfering RNA comprises a positive-sense strand and an antisense strand, the positive-sense strand and the antisense strand are at least partially reversely complementary to form a double-strand region, the positive-sense strand or the antisense strand is composed of 19 complementary nucleotide sequences of nucleotide flat ends, or the nucleotide sequence is composed of 21-27 nucleotide sequences with protruding ends. The small interfering RNA disclosed by the invention directly acts on a key molecule, namely TRPV1 channel protein, causing the xerophthalmia symptom by specifically inhibiting the expression of the TRPV1 gene, so that pain and inflammatory response are fundamentally reduced. The curative effect is lasting, the side effect is low, and the patient compliance is high.
Need to check novelty before this filing date? Find Prior Art